Uses

Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, including newly diagnosed, previously treated disease, and cases with the T315I mutation.

Do not use if

No specific contraindications are listed in the prescribing information.

Side effects

Myelosuppression, pancreatic toxicity, hypertension, hypersensitivity reactions, and cardiovascular adverse effects may occur.

Warnings

Monitor blood counts, pancreatic enzymes, and blood pressure regularly during treatment.

How it works

Asciminib is a BCR-ABL1 tyrosine kinase inhibitor that binds the ABL myristoyl pocket and inhibits leukemic cell signaling.

Storage

Store at controlled room temperature in the original container.